Source-grounded facts extracted from HARVARD BIOSCIENCE INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HARVARD BIOSCIENCE INC shareholders approved Approval of the Amended and Restated 2021 Incentive Plan at the 2026-06-02 meeting.
“Proposal 5 – Approval of the Amended and Restated 2021 Incentive Plan The Company’s stockholders approved the Amended and Restated 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,131,261 680,030 17,700 970,538”
HARVARD BIOSCIENCE INC shareholders approved Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan at the 2026-06-02 meeting.
“Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538”
HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers at the 2026-06-02 meeting.
“Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved the compensation of the Company’s named executive officers by a non-binding advisory vote, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,768,695 57,111 3,185 970,538”
HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP at the 2026-06-02 meeting.
“Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: Votes For Votes Against Votes Abstained 2,781,705 13,975 3,849”
HARVARD BIOSCIENCE INC shareholders approved Election of two Class II Directors at the 2026-06-02 meeting.
“On June 2, 2026, the Company held its Annual Meeting, at which the Company’s stockholders voted on five proposals that are described in detail in the Definitive Proxy Statement. The voting results for each of the proposals are reported below. Proposal 1 - Election of Directors The Company’s stockholders elected two Class II Directors for three-year terms, such terms to continue until the annual meeting of stockholders in 2029 and until such Directors’ successors are duly elected and qualified or until his or her earlier resignation or removal: Name Votes For Votes Withheld Broker Non-Votes John Duke 1,800,288 28,703 970,538 Katherine A. Eade 1,680,982 148,009 970,538”
HARVARD BIOSCIENCE INC reported the first quarter ended March 31, 2026 results: revenue $20.8 million, net income $(3.4) million. Guidance reaffirmed.
“margin NPI sales growth driving bottom line growth in the second half of the year.” First Quarter 2026 Results For the first quarter of 2026, the Company reported revenues of $20.8 million compared to $21.8 million in the first quarter of 2025. Gross margin for the first quarter of 2026 was 59%, compared to 56% in the first quarter of 2025. Net loss for the first”
HARVARD BIOSCIENCE INC reported financial results for three and twelve months ended December 31, 2025.
“On March 12, 2026, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and twelve months ended December 31, 2025, and the details of a related conference call to be held at 8:00 AM ET on March 12, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.”
HARVARD BIOSCIENCE INC announced a restructuring with charges of $3.4 to $4.4 million affecting manufacturing operations (targeted reconfiguration of the Company’s workforce across impacted operations).
“of the Company’s workforce across impacted operations. The Company expects to incur pre-tax restructuring charges related to Project Viking in the range of approximately $3.4 to $4.4 million, including non-cash asset write-off and/or accelerated depreciation charges in the range of approximately $0.6 to $0.7 million, primarily related to the exit of”
HARVARD BIOSCIENCE INC: Reduced quorum requirement for stockholder meetings from a majority to one-third of shares entitled to vote (effective 2026-01-19).
“On January 19, 2026, the Board of Directors (the “Board”) of Harvard Bioscience, Inc., a Delaware corporation (the “Company”), approved an amendment to the Company’s Amended and Restated By-laws to reduce the quorum requirement for stockholder meetings from a majority to one-third (1/3) of the shares of capital stock entitled to vote (the “By-laws Amendment”).”
HARVARD BIOSCIENCE INC entered into Loan and Security Agreement with certain financial institutions party thereto as lenders and BroadOak Income Fund, L.P., as administrative agent valued at $10.0 million, $22.5 million and $7.5 million (effective 2025-12-17).
“On December 17, 2025, Harvard Bioscience, Inc. (the “Company”), as borrower, entered into a Loan and Security Agreement (the “Loan Agreement”) with certain financial institutions party thereto as lenders (the “Lenders”) and BroadOak Income Fund, L.P. (“BroadOak”), as the administrative agent and collateral agent”
HARVARD BIOSCIENCE INC incurred convertible notes of $7.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
“The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan””
HARVARD BIOSCIENCE INC incurred term loan of $22.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
“The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan””
HARVARD BIOSCIENCE INC incurred term loan of $10.0 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
“The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan””
HARVARD BIOSCIENCE INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026 (the “Second Compliance Period”), to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting”
HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).
“June 18, 2025, Harvard Biosci e nce, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”) due to the Company having only two members on the audit committee (the “Audit Committee”) of its Board of Directors (the “Board”). The Company’s current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick’s resignation from the Board and the Audit Committee effe”
Alan Edrick resigned as Director at HARVARD BIOSCIENCE INC.
“On June 10, 2025, Alan Edrick resigned from the board of directors of Harvard Bioscience, Inc. (the “Company”), effective June 10, 2025.”
Katherine Eade was appointed as Lead Independent Director at HARVARD BIOSCIENCE INC.
“One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.”
John D. Duke was appointed as Director at HARVARD BIOSCIENCE INC.
“On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.”
Thomas Loewald resigned as Director at HARVARD BIOSCIENCE INC.
“On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.”
Bertrand Loy departed as Lead Independent Director at HARVARD BIOSCIENCE INC.
“On April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting.”
HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 4, 2025, Harvard Bioscience, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the d”
Mark Frost was appointed as Interim Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).”
Jennifer Cote resigned as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.”
HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Named Executive Officers at the 2024-05-14 meeting.
“Votes For Votes Against Votes Abstained Broker Non-Votes 27,472,149 903,608 2,208,314 4,292,458”
HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP as independent registered public accounting firm at the 2024-05-14 meeting.
“Votes For Votes Against Votes Abstained 34,794,995 73,003 8,531 Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation”
HARVARD BIOSCIENCE INC shareholders approved Election of Class III Director Alan Edrick at the 2024-05-14 meeting.
“Name Votes For Votes Withheld Broker Non-Votes Alan Edrick 19,722,574 10,861,497 4,292,458”
HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2024 results: revenue $24.5, net income $(4.7), EPS $(0.11) per diluted share.
“continue to expect solid growth in the second half.” Financial Results Summary Three Months Ended March 31, (unaudited, $ in millions except per share data) 2024 2023 Revenues $ 24.5 $ 30.0 Gross margin 60.3 % 61.2 % Operating (loss) income (GAAP) $ (2.3 ) $ 1.7 Adjusted operating income $ 1.2 $ 4.4 Net (loss) income (GAAP) $ (4.7 ) $ 0.6 Diluted (loss)”
HARVARD BIOSCIENCE INC amended Third Amendment with Citizens Bank, N.A. (effective 2024-03-28).
“On March 28, 2024, Harvard Bioscience, Inc. (the “Company”) entered into a third amendment (the “Third Amendment”) to the Credit Agreement (the “Credit Agreement”), dated as of December 22, 2020, among the Company, the lenders party thereto (the “Lenders”), and Citizens Bank, N.A., as the administrative agent”
HARVARD BIOSCIENCE INC reported the fiscal year ended December 31, 2023 results: revenue $112.3 million, net income $(3.4) million, EPS $(0.08) per diluted share. Guidance initiated.
“in the same period last year. Debt was reduced by $2.3 million during the quarter. Year Ended December 31, 2023 Highlights For the year ended December 31, 2023, revenues were $112.3 million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from discontinued products compared to 2022. Gross margin”
HARVARD BIOSCIENCE INC reported the fourth quarter ended December 31, 2023 results: revenue $28.2 million, net income $(1.8) million, EPS $(0.04) per diluted share.
“a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow”
HARVARD BIOSCIENCE INC reported full year 2023 results: revenue ~ $112.3M incl. $5.1M net discontinued*.
“Est. FY’23 Revenue: ~ $112.3M incl. $5.1M net discontinued*”
HARVARD BIOSCIENCE INC updated its fiscal 2023 guidance (reaffirmed).
“we now expect our fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5 percentage point headwind from discontinued products. For the year 2023, we continue to expect gross margins of approximately 60%. We now expect adjusted EBITDA margins in the 13% to 14% range.”
HARVARD BIOSCIENCE INC reported the nine months ended September 30, 2023 results: revenue $84.1 million, net income ($1.6) million, EPS $(0.04).
“debt was reduced by $3.8 million during the third quarter of 2023. Nine Months ended September 30, 2023 Highlights For the nine months ended September 30, 2023, revenues were $84.1 million, compared to $84.9 million in the same period a year ago. Revenues for the nine months ended September 30, 2023 include a net reduction of $4.1 million from discontinued products”
HARVARD BIOSCIENCE INC reported the third quarter ended September 30, 2023 results: revenue $25.4 million, net income ($1.2) million, EPS $(0.03).
“a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2023 Financial Results · Q3 Revenues of $25.4 million · Q3 Gross Margin of 58.1% · Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million · Continued strong operating cash flow drove debt reduction of $8.3”
Jennifer Cote was appointed as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On June 20, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer effective as of June 19, 2023.”
HARVARD BIOSCIENCE INC shareholders voted on Recommendation, by Non-Binding Advisory Vote, of the Frequency (One, Two or Three Years) of the Shareholder Vote on the Compensation of the Named Executive Officers at the 2023-05-15 meeting.
“Proposal 4 –Recommendation, by Non-Binding Advisory Vote, of the Frequency (One, Two or Three Years), of the Shareholder Vote on the Compensation of the Named Executive Officers The Company’s stockholders recommended a frequency of one year for the stockholder vote on the compensation of the Company’s named executive officers, by a non-binding advisory vote: Votes For 1 Year Votes For 2 Years Votes For 3 Years Votes Abstained Broker Non-Votes 25,372,472 24,073 1,498,941 240,001 6,260,898”
HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Named Executive Officers at the 2023-05-15 meeting.
“Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Named Executive Officers The Company’s stockholders approved the compensation of the Company’s named executive officers, by a non-binding advisory vote: Votes For Votes Against Votes Abstained Broker Non-Votes 26,568,836 531,708 34,943 6,260,898”
HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-15 meeting.
“Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. There were no broker non-votes on this proposal. Votes For Votes Against Votes Abstained 33,325,418 9,580 61,387”
HARVARD BIOSCIENCE INC shareholders approved Election of Class II Directors for a three-year term at the 2023-05-15 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected two Class II Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such director’s successor is duly elected and qualified or until his or her earlier resignation or removal. Name Votes For Votes Withheld Broker Non-Votes Katherine A. Eade 24,519,192 2,616,295 6,260,898 Thomas W. Loewald 25,564,902 1,570,585 6,260,898”
HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2023 results: revenue $30.0 million, net income $0.6 million, EPS $0.01. Guidance initiated.
“a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces First Quarter 2023 Financial Results • Q1 Revenues of $30 million up 4% over prior year period • Q1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior year • Q1 Adjusted Operating Income of $4.4 million up from $2.4”
HARVARD BIOSCIENCE INC reported the fourth quarter and year ended December 31, 2022 results: revenue $28.4 million, net income $(1.7) M, EPS $(0.04).
“Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular”
Michael Rossi resigned as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as the Company’s Chief Financial Officer and Treasurer effective December 31, 2022.”
Jennifer Cote was appointed as Interim Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On December 8, 2022, the Company appointed Jennifer Cote to serve as Interim Chief Financial Officer and Treasurer effective upon Mr. Rossi’s resignation.”
Michael Rossi resigned as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.
“On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as Chief Financial Officer and Treasurer, effective December 31, 2022.”
HARVARD BIOSCIENCE INC reported the third quarter ended September 30, 2022 results: revenue $26.9 million, EPS $ (0.08 ). Guidance initiated.
“Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2022. Jim Green, Chairman and CEO, said, "Impacted by a challenging summer, our third quarter revenues were $26.9 million, down 9% from the same quarter prior year. Growth of 6% in our cellular/molecular product revenues were more than offset by a 17% reduction in sales of our higher margin pre-clinical products and a negative currency impact of approximately $1.0 million. Gross margin was down on lower revenue as well as higher costs of labor and materials, in addition to inventory charges related to the discontinuation of certain non-strategic products as a result of our previously communicated portfolio optimization. Operating margin was down from last year mainly on lower sales and lower gross margin." Green continued, "In spite of headwinds in the quarter, we expect sequential revenue growth and an improved product mix in Q4 resulting in our gross mar”
Ken Olson resigned as Chief Operating Officer at HARVARD BIOSCIENCE INC.
“On January 24, 2022, Harvard Bioscience, Inc. (the “Company”) accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.